Molecules, Vol. 23, Pages 2072: Antihyperalgesic Activity of Atomoxetine on Diabetes-Induced Neuropathic Pain: Contribution of Noradrenergic and Dopaminergic Systems
Molecules, Vol. 23, Pages 2072: Antihyperalgesic Activity of Atomoxetine on Diabetes-Induced Neuropathic Pain: Contribution of Noradrenergic and Dopaminergic Systems
Molecules doi: 10.3390/molecules23082072
Authors:
Mustafa Burak Barbaros
Özgür Devrim Can
Umut İrfan Üçel
Nazlı Turan Yücel
Ümide Demir Özkay
Atomoxetine is a selective noradrenaline reuptake inhibitor drug. Based on the knowledge that agents increasing monoamine levels in the central nervous system have therapeutic potential for neuropathic pain, it is planned to investigate the possible efficacy of atomoxetine on diabetes-induced hyperalgesia, in this study. Randall-Selitto (mechanical noxious stimuli) and Hargreaves (thermal noxious stimuli) tests were used to evaluate nociceptive perception of rats. Obtained data indicated that streptozotocin-induced diabetes causes significant decreases in the paw withdrawal threshold and paw withdrawal latency values of the animals, respectively. However, atomoxetine administered at 3 mg/kg/day for 7 and 14 days improved these diabetes-induced hyperalgesia responses. Furthermore, antihyperalgesic activity was antagonized with α-methyl-para-tyrosine methyl ester, phentolamine, propranolol, and sulpiride pre-treatments. The same effect was not reversed, however, by SCH 23390. These findings demonstrated, for the first time, that atomoxetine possesses significant antihyperalgesic activity on diabetes-induced neuropathic pain and this effe...
Source: Molecules - Category: Chemistry Authors: Mustafa Burak Barbaros Özgür Devrim Can Umut İrfan Üçel Nazl ı Turan Yücel Ümide Demir Özkay Tags: Article Source Type: research
More News: Brain | Clinical Trials | Diabetes | Endocrinology | Inderal | Neurology | Pain | Strattera | Study